• United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised options for 9,500 shares at USD 146.03 on June 12, 2026.
• Rothblatt sold 9,500 shares in multiple trades at weighted-average prices ranging from USD 537.4 to USD 545.71.
• Directly held common shares fell to 40,513 following the transactions.
• Directly held stock options declined to 40,910 following the exercise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000078), on June 15, 2026, and is solely responsible for the information contained therein.